Strata Critical Medical, Inc. Fundamental Analysis (NASDAQ: SRTA)
Strata Critical Medical, Inc. Fundamental Analysis (NASDAQ: SRTA)
Strata Critical Medical, Inc. (NASDAQ: SRTA) shows moderate financial fundamentals with a PE ratio of 11.83, profit margin of 15.71%, and ROE of 14.27%. The company generates $0.3B in annual revenue with weak year-over-year growth of -20.73%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 34.4/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SRTA's fundamental strength across five key dimensions:
Efficiency Score
ExcellentSRTA demonstrates superior asset utilization.
Valuation Score
ExcellentSRTA trades at attractive valuation levels.
Growth Score
ModerateSRTA shows steady but slowing expansion.
Financial Health Score
ExcellentSRTA maintains a strong and stable balance sheet.
Profitability Score
WeakSRTA struggles to sustain strong margins.
Key Financial Metrics
Is SRTA Expensive or Cheap?
P/E Ratio
SRTA trades at 11.83 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SRTA's PEG of 0.04 indicates potential undervaluation.
Price to Book
The market values Strata Critical Medical, Inc. at 1.82 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -55.89 times EBITDA. This is generally considered low.
How Well Does SRTA Make Money?
Net Profit Margin
For every $100 in sales, Strata Critical Medical, Inc. keeps $15.71 as profit after all expenses.
Operating Margin
Core operations generate -7.97 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $14.27 in profit for every $100 of shareholder equity.
ROA
Strata Critical Medical, Inc. generates $12.09 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Strata Critical Medical, Inc. generates limited operating cash flow of $-31.02M, signaling weaker underlying cash strength.
Free Cash Flow
Strata Critical Medical, Inc. generates weak or negative free cash flow of $-43.86M, restricting financial flexibility.
FCF Per Share
Each share generates $-0.51 in free cash annually.
FCF Yield
SRTA converts -8.57% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
11.83
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.04
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.82
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.00
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.02
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.64
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.14
vs 25 benchmark
ROA
Return on assets percentage
0.12
vs 25 benchmark
ROCE
Return on capital employed
-0.07
vs 25 benchmark
How SRTA Stacks Against Its Sector Peers
| Metric | SRTA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 11.83 | 31.57 | Better (Cheaper) |
| ROE | 14.27% | 438.00% | Weak |
| Net Margin | 15.71% | 24098.00% | Weak |
| Debt/Equity | 0.02 | 0.53 | Strong (Low Leverage) |
| Current Ratio | 2.64 | 5.57 | Strong Liquidity |
| ROA | 12.09% | -195.00% (disorted) | Strong |
SRTA outperforms its industry in 4 out of 6 key metrics, particularly excelling in ROA, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Strata Critical Medical, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
231.70%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
187.76%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
-166.30%
Industry Style: Defensive, Growth, Innovation
Declining